Home › Compare › LLY vs JNJ

LLY vs JNJ — Head-to-Head 2026

Eli Lilly vs Johnson & Johnson: OVR ratings, revenue growth, valuation, and volatility compared.

LLY — Obesity drug empire. Mounjaro/Zepbound demand exceeds supply. OVR: 91 (S-Tier).

JNJ — 62 consecutive years of dividend increases. Pharma + MedTech. OVR: 85 (A-Tier).

HEAD-TO-HEAD

METRICLLY — Eli LillyJNJ — Johnson & Johnson
OVR Rating9185
TierS-TierA-Tier
Momentum Score80/10045/100
Stability Score85/10092/100
Value Score50/10075/100
Revenue Growth+36%+5%
P/E Ratio48x14x
Beta0.650.45
Market Cap$740B$380B
Dividend Yield0.6%3.3%
S&P 500YesYes

FREQUENTLY ASKED QUESTIONS

Which is stronger, LLY or JNJ?
MarketMVP rates LLY at 91 OVR (S-Tier) and JNJ at 85 OVR (A-Tier). LLY scores higher.
Is LLY more volatile than JNJ?
LLY beta: 0.65. JNJ beta: 0.45. LLY is more volatile.
Which has higher revenue growth?
LLY: +36%. JNJ: +5%. LLY is growing faster.
EXPLORE BOTH ON MARKETMVP →
LLY Full Analysis JNJ Full Analysis All Comparisons

Educational purposes only. MarketMVP OVR scores and ratings are educational tools — not financial advice or recommendations. Always do your own research. Full disclaimer